XML 24 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements Of Operations (USD $)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended 120 Months Ended
Dec. 31, 2011
Dec. 31, 2010
Dec. 31, 2011
Costs and expenses:      
Research and development $ 2,315 $ 3,106 $ 41,585
Selling, general and administrative 5,046 6,069 39,356
Merger transaction costs     5,470
Restructuring expense, net     2,413
Loss on impairment of in-process research and development     6,000
Total costs and expenses 7,361 9,175 94,824
Loss from operations (7,361) (9,175) (94,824)
Gain on assignment of patent rights 2,000   2,000
Gain on bargain purchase     25,282
Interest and other income 2 763 2,026
Interest and other expense (5) (8) (439)
Loss before income taxes (5,364) (8,420) (65,955)
Benefit from income taxes     2,281
Net loss (5,364) (8,420) (63,674)
Less: Accretion of redeemable convertible preferred stock     (245)
Less: Deemed preferred stock dividend for additional common shares issuable under anti-dilution provisions     (781)
Net loss available to common stockholders $ (5,364) $ (8,420) $ (64,700)
Net loss available to common stockholders per share:      
Basic and diluted $ (0.53) $ (0.99)  
Weighted average shares outstanding:      
Basic and diluted 10,038,243 8,506,320